News & Updates
Filter by Specialty:
Chlormadinone prolongs active surveillance, maintains QoL in men with prostate cancer
Use of the oral antiandrogen chlormadinone at a low dose led to improvements in persistence rate of active surveillance (AS), PSA* and testosterone levels and prostate volume, and quality of life (QoL) in men with low-risk prostate cancer (PCa), the PROSAS study has shown.
Chlormadinone prolongs active surveillance, maintains QoL in men with prostate cancer
05 Nov 2021Weight, OGTT values predict need for insulin therapy among women with GDM
Pregnant women with gestational diabetes mellitus (GDM) who are overweight and have increased blood glucose, as measured by the Oral Glucose Tolerance Test (OGTT), are highly likely to require subsequent insulin therapy, according to a study.
Weight, OGTT values predict need for insulin therapy among women with GDM
05 Nov 2021Add-on brivaracetam for epilepsy makes good in real-world practice
Long-term postmarketing data for adjunctive brivaracetam show that its use helps improve seizure control in patients with various epilepsy syndromes, even in those with prior exposure to levetiracetam. However, psychobehavioural adverse events (AEs) occur in one out of ten patients.
Add-on brivaracetam for epilepsy makes good in real-world practice
02 Nov 2021Do mRNA COVID-19 vaccines influence treatment for rheumatic diseases?
In individuals receiving disease-modifying antirheumatic drugs* (DMARDs) for inflammatory rheumatic diseases** (IRD), humoral response remained satisfactory following administration of the second dose of the Pfizer mRNA vaccine against SARS-CoV-2, a study suggests.
Do mRNA COVID-19 vaccines influence treatment for rheumatic diseases?
02 Nov 2021Pembrolizumab extends RFS in stage II melanoma
Pembrolizumab extended recurrence-free survival (RFS) in patients with high-risk stage II melanoma who had undergone complete resection, interim analysis results of the phase III KEYNOTE-716 trial showed.
Pembrolizumab extends RFS in stage II melanoma
01 Nov 2021Sustained benefit with anti-TNFα less likely to lead to subsequent loss of response in IBD
Inflammatory bowel disease (IBD) patients receiving treatment with antitumour necrosis factor alpha (anti-TNFα) for more than 2 years represent a distinct group who obtain prolonged clinical benefit and tolerate maintenance treatment, according to a study.